Bio Fluid ventures into pharmaceutical, developing a novel antidiabetic medicine. [Website] (2022)
Abstract
Bio Fluid Sdn Bhd has signed a Memorandum of Agreement (MOA) with UiTM to further develop a new oral medication that will give hope to diabetic patients. It is part of UiTM’s effort through the Business Innovation & Technology Commercialization Center (BiTCOM) to accelerate the translation of important discoveries arising from research and innovation for the benefit of the country and the global community. This collaboration will see commercialisation efforts between UiTM innovations and research products where the licensing agreement is valued at RM1,060,000.00. The new drug developed has a high potential to be more effective than the standard drugs (insulin and metformin) in improving hyperglycaemia, hyperlipidemia without compromising tissues structure and function. More products will be developed within the health care and pharmaceuticals segment, including anti-inflammation spray, functional food, booster drink, and many more.
| Item Type: | Website |
|---|---|
| Keywords: | Health innovation, Health solutions, Oral medication, Ganoringa, Antidiabetic medicine, Pharmaceuticals |
| Taxonomy: | By Niche > Health Innovation > Health Research By Niche > Health Innovation > Medical Care > Technological Innovations |
| Local Content Hub: | Niche > Health Innovation |
| Depositing User: | Nur Ira Wahidah Nasir (Hospital UiTM) |
| Date Deposited: | 16 Feb 2023 11:40 |
| Last Modified: | 16 Feb 2023 11:40 |
| Related URLs: |
Actions (login required)
 |
View Item |